Clorox fiscal 2027 outlook: inflation and value shoppers weigh
Clorox forecast a difficult fiscal 2027, citing inflation and consumers shifting to value. The company expects net sales up 13% to 14% for fiscal 2027, with about 9.5 points from its April 2026 GOJO Industries acquisition. Adjusted EPS is projected at $5.70 to $6.00, GAAP diluted EPS $5.41 to $5.71. Q4 revenue fell 2% to $1.95B; adjusted EPS was $1.66.
How this was made
The 30-second read
Why it matters
Management framed fiscal 2027 as challenging due to inflation volatility and a value-seeking consumer, while forecasting gross margin around 42% and modest organic sales growth.
Market read
This is a fresh, quantified outlook update that highlights margin risk and low organic momentum, with earnings growth partly driven by acquisition and prior-year lapping effects.
What to watch
Organic sales growth is expected to be boosted by lapping the prior year ERP-related inventory drawdown, so investors should separate underlying demand trends from accounting and timing effects.
Background
Clorox completed the GOJO Industries acquisition in April 2026, adding Purell and expanding its health and hygiene mix.
Ticker impact
Clorox guided fiscal 2027 adjusted EPS to $5.70 to $6.00 and warned inflation and value-focused demand will offset cost savings.
Near-term bias lower until investors gain confidence that cost savings can offset inflation and mix headwinds.
The company explicitly forecasts gross margin around 42% despite cost savings, and organic sales are expected to grow only 3.5% to 4.5% with much of the growth tied to lapping prior ERP-related inventory effects.
Market effects
Signals continued pricing and mix pressure for consumer staples personal care, especially where inflation and value trade-down are relevant.
Primarily US consumer demand sensitivity, with no direct regional-specific catalyst beyond domestic value-shopping behavior.
Limited direct global read-through, but inflation and mix dynamics can affect multinational hygiene and household product peers.
Counterpoint
The guidance still shows net sales growth of 13% to 14% largely supported by the GOJO acquisition, which could cushion earnings even if organic demand is weak.
Key entities
- companyClorox
Guided fiscal 2027 net sales, EPS, and gross margin, citing inflation and value-focused demand as offsets to cost savings.
- companyGOJO Industries
Acquisition source of Purell and health and hygiene portfolio, contributing roughly 9.5 percentage points of fiscal 2027 net sales growth.
